LMNA Variants Contribute to Polycystic Ovary Syndrome Pathogenesis

Overview

Rare LMNA gene variations are implicated in the development of polycystic ovary syndrome (PCOS), particularly in non-obese women. These variants affect adipogenesis, leading to ectopic fat deposition and insulin resistance, highlighting distinct PCOS subtypes with therapeutic implications.

Background

LMNA encodes lamin A/C, proteins essential for adipose tissue development and function. Loss-of-function mutations in LMNA cause partial lipodystrophy characterized by abnormal fat distribution and insulin resistance. PCOS is a heterogeneous endocrine disorder with variable presentations influenced by adipose tissue capacity and lipid storage. Understanding genetic contributions such as LMNA variants aids in refining PCOS diagnosis and treatment.

Data Highlights

Bauer et al analyzed 1529 PCOS cases from two cohorts and found that pathogenic LMNA variants (R25L, R401C, R435C, R482Q, T528R, R571S) were significantly more prevalent in the lowest BMI quartile (7 of 383) compared to higher BMI quartiles (1 of 1146), with P < .0001.

Key Findings

• LMNA loss-of-function mutations cause partial lipodystrophy with abnormal fat distribution and insulin resistance.
• Pathogenic LMNA variants are more frequent in PCOS patients with lower BMI, indicating a non-obese PCOS subtype.
• PCOS pathogenesis involves a mismatch between early adipogenesis and later lipogenesis, influenced by lamin A/C function.
• PCOS variants linked to reduced adipogenesis tend to occur without obesity, whereas those linked to augmented lipogenesis are associated with obesity.
• Therapeutic approaches differ: adipogenesis-enhancing treatments like pioglitazone may benefit non-obese PCOS patients with LMNA variants, unlike standard treatments targeting the gonadotropic axis or appetite.

Clinical Implications

Clinicians should consider genetic testing for LMNA variants in PCOS patients, especially those without obesity, to guide personalized treatment. Enhancing adipogenesis with medications such as pioglitazone may be more effective in this subgroup than conventional therapies. Assessment of insulin sensitivity and adipose tissue distribution remains important in PCOS evaluation.

Conclusion

LMNA gene variants contribute significantly to the development of PCOS, particularly in non-obese women, by impairing adipogenesis and promoting ectopic fat accumulation. Recognizing this subtype can inform targeted therapeutic strategies to improve patient outcomes.

References

1. Bauer et al 2023 -- LMNA Variants in PCOS
2. Gambineri et al 2008 -- LMNA-related PCOS and Insulin Sensitivity